CureMatch Launches Decision Support Platform to Harness the Power of Personalized Medicine in Cancer Care
CureMatch is the first and only company to provide a comprehensive decision support system ranking personalized combination therapy options
SAN DIEGO, CA – March 7, 2017 –CureMatch today announced the launch of their decision support software platform for the selection of combinations of cancer-fighting drugs; personalized for individual patients based on the molecular profile of the patient’s tumor. The CureMatch platform is a comprehensive solution that couples expertise in oncology, genetics, proteomics, biochemistry, and cell biology with extraordinary computation power. The result is an easy to read report delivered to the oncologist with a ranking of the best matched combination therapy options. Personalized combination therapy has been shown in studies to have higher response and survival rates than traditional chemotherapy or targeted monotherapies.
“We now recognize that cancer is a highly individualized disease,” said Blaise Barrelet, Chief Executive Officer and Chairman of the Board of CureMatch. “Patients have traditionally been treated with a one-size-fits-all treatment of chemotherapy, aimed largely at fighting a particular type or origin of cancer. This is old thinking with highly limited positive results.”
The CureMatch decision support system enables a new approach to cancer treatment. The stage and type of cancer determines whether single therapy or combination therapy is needed. CureMatch combs through millions of drug combinations using data from clinical trials, publications and drug interactions and analyzes them against the patient’s genetic profile to determine the best course of treatment. With matched combination therapy, each drug is able to target individual cancer mutations. Further, when drugs with different effects are combined, each drug can be used at its optimal dose, without intolerable side effects.
“It is an exciting time with rapid advancements in technology for personalized cancer care,” said Barrelet. “Our CureMatch platform is meeting a growing need to leverage these advances, by matching mono or combination cancer therapies to an individual’s own tumor and aiding the oncologists in optimizing cancer treatment and improving patient outcomes.”
About CureMatch
CureMatch™, Inc. is a San Diego-based digital health company focused on personalized medicine and combination therapy in oncology. CureMatch’s Decision Support System guides oncologists in the selection of cancer drugs that are customized for individual patients based on their molecular tumor profile. CureMatch enables oncologists to become experts in personalized medicine by providing them with actionable intelligence towards advanced cancer treatment options. For more information visit www.curematch.com.
Media Contact
Martin Culjat
(858)859-2873
press@curematch.com